Strategic Stealth & Roadmap

Transparency On Our Current Development Position

We have received questions about the absence of publications and public datasets. The answer is not procedural — it is methodological. Evaluating a deterministic integration architecture built on established physics by how much it innovates relative to the literature is like judging a fish by its ability to climb a tree. The wrong metric produces the wrong assessment. The correct comparison is not with the literature — it is with the operational gap that the literature describes and does not resolve. When we produce data in an industrial environment, that gap is what we will ask to be evaluated against. The reasoning behind this position is developed in Reading AFRM® through Innovation Theory.

Engineering Philosophy Architectural Framework

AFRM® is based on the working hypothesis that fouling dynamics in TFF can be addressed through structured process control logic, complementing traditional material and membrane optimization approaches.

The architecture has been developed under two primary engineering constraints:

• 1
  Regulatory Compatibility Control behavior must remain predictable, reproducible, and documentable within GMP manufacturing environments.
• 2
  Analytical Signal Discrimination The control framework is designed to differentiate membrane fouling phenomena from instrumentation drift or sensor artifacts, reducing the risk of inappropriate corrective interventions.

If the module cannot operate within its design conditions, the process continues uninterrupted in standard TFF mode. The operator receives an immediate notification and retains full batch responsibility at all times.

This is a direct consequence of a broader design principle: the deterministic engineering approach was developed for framework universality, not for performance optimization on a single fluid class. A system that requires retuning for every new feed is not a platform — it is a workaround. In physical terms, AFRM® is nothing more than an intelligent tube — the complexity is entirely in the engineering logic that governs it, not in the materials or infrastructure it requires. That is precisely what makes it transferable.

Reducing the hardware footprint to its essential elements is not a constraint — it is the direct consequence of having resolved process complexity at the architectural level. What appears simple in the module is the outcome of rigorous engineering, not its absence.

When a new biofluid class is introduced, the corresponding process parameters are derived from peer-reviewed rheological literature and integrated into the validated configuration before the run. This is not retuning — it is the standard characterization step that any TFF process requires, resolved analytically rather than empirically at process time.

Current Phase Development Status

The theoretical modeling phase and computational structuring of the fouling mechanism have been completed.

Internal controlled laboratory testing has been conducted on representative biofluid models — including extracellular vesicles, viral vectors, protein secretomes, and high-viscosity matrices — to evaluate the coherence between the mathematical framework and observed system behavior under defined conditions. These tests produced the preliminary performance data referenced in the Technical White Paper, including flux recovery figures. This data is preliminary: it was obtained under controlled laboratory conditions, not under production-relevant constraints, and has not been independently validated.

We publish these figures transparently because they are the honest output of the work completed to date. We do not present them as industrial validation, which does not yet exist and which is the explicit objective of the next phase.

Industrial-scale replication under production-relevant constraints — with CDMOs or membrane manufacturers — is the objective of the current outreach phase, targeted for H2 2026. AFRM® is an add-on, not a process change. The CDMO phase has no black swans — the unknowns are engineering parameters, known, measurable, bounded.

AFRM® is designed for component-level qualification — not process change validation. The certification roadmap following CDMO validation targets recognition as utility equipment under standard bioprocessing qualification frameworks, reducing integration burden for industrial partners to gap analysis and simplified qualification protocols.

Industrial partners interested in structured collaboration are invited to reach out directly.

Next Phase Roadmap

The current phase is oriented toward structured industrial collaboration with CDMOs and membrane manufacturers to generate empirical datasets under manufacturing conditions.

The objective is controlled validation and integration assessment within existing facility capabilities. Discussions are ongoing; no partnership has been announced at this stage.

Our approach remains strictly technical: measurable behavior, documented repeatability, and compatibility with regulatory frameworks.